MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer

Oncotarget

Volumn 6, Issue 1, 2015, Pages 441-457

  Chen, Wei Yu ^a,b   Liu, Shih Yang ^c   Chang, Yung Sheng ^d   Yin, Juan Juan ^e   Yeh, Hsiu Lien ^f   Mouhieddine, Tarek H ^g   Hadadeh, Ola ^g   Abou Kheir, Wassim ^g   Liu, Yen Nien ^d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^g AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

BIRC5; Bone metastasis; miR 34a; Prostate cancer; TCF7

Indexed keywords

MICRORNA 34A; RAS PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 1; WNT PROTEIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MICRORNA; MIRN34 MICRORNA, HUMAN; TCF7 PROTEIN, HUMAN; TRANSCRIPTION FACTOR 7;

3' UNTRANSLATED REGION; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BIRC5 GENE; BONE METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROSTATE CANCER; RAS ACTIVATED PROSTATE CANCER; REGULATORY MECHANISM; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANIMAL; BONE TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RAS PROTEINS; SIGNAL TRANSDUCTION; T CELL TRANSCRIPTION FACTOR 1; TRANSFECTION; WNT PROTEINS;

EID: 84921370750     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2690     Document Type: Article

References (56)

1. Gittes RF. Carcinoma of the prostate. N Engl J Med. 1991; 324:236-245.
2. Barthel SR, Hays DL, Yazawa EM, Opperman M, Walley KC, Nimrichter L, Burdick MM, Gillard BM, Moser MT, Pantel K, Foster BA, Pienta KJ, Dimitroff CJ. Definition of molecular determinants of prostate cancer cell bone extravasation. Cancer Res. 2013; 73:942-952.
3. Carter BS, Epstein JI, Isaacs WB. Ras gene mutations in human prostate cancer. Cancer Res. 1990; 50:6830-6832.
4. Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH. Infrequent ras oncogene mutations in human prostate cancer. Prostate. 1992; 20:327-338.
5. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M, Wu H. Pten loss and ras/mapk activation cooperate to promote emt and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012; 72:1878-1889.
6. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18:11-22.
7. Jiang H, Grenley MO, Bravo MJ, Blumhagen RZ, Edgar BA. Egfr/ras/mapk signaling mediates adult midgut epithelial homeostasis and regeneration in drosophila. Cell Stem Cell. 2011; 8:84-95.
8. Roberts PJ, Der CJ. Targeting the raf-mek-erk mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26:3291-3310.
9. Anastas JN, Moon RT. Wnt signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013; 13:11-26.
10. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC. Regulation of cyclooxygenase-2 expression by the wnt and ras pathways. Cancer Res. 2003; 63:728-734.
11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-myc as a target of the apc pathway. Science. 1998; 281:1509-1512.
12. Kerkhoff E, Houben R, Loffler S, Troppmair J, Lee JE, Rapp UR. Regulation of c-myc expression by ras/raf signalling. Oncogene. 1998; 16:211-216.
13. Kypta RM, Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol. 2012.
14. Polakis P. Wnt signaling and cancer. Genes Dev. 2000; 14:1837-1851.
15. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene. 1999; 18:2883-2891.
16. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin d1 in colon carcinoma cells. Nature. 1999; 398:422-426.
17. Galceran J, Farinas I, Depew MJ, Clevers H, Grosschedl R. Wnt3a-/-like phenotype and limb deficiency in lef1(-/-) tcf1(-/-) mice. Genes Dev. 1999; 13:709-717.
18. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. Microrna in prostate, bladder, and kidney cancer: A systematic review. Eur Urol. 2011; 59:671-681.
19. Kennell JA, Gerin I, MacDougald OA, Cadigan KM. The microrna mir-8 is a conserved negative regulator of wnt signaling. Proc Natl Acad Sci U S A. 2008; 105: 15417-15422.
20. Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, Kang SE, Cha SY, Ryu JK, Na JM, Park C, Kim K, Lee S, Gumbiner BM, Yook JI, Weiss SJ. P53 and microrna-34 are suppressors of canonical wnt signaling. Sci Signal. 2011; 4:ra71.
21. Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, Hermeking H. Detection of mir-34a promoter methylation in combination with elevated expression of c-met and beta-catenin predicts distant metastasis of colon cancer. Clin Cancer Res. 2013; 19:710-720.
22. Hermeking H. The mir-34 family in cancer and apoptosis. Cell Death Differ. 2010; 17:193-199.
23. Cheng CY, Hwang CI, Corney DC, Flesken-Nikitin A, Jiang L, Oner GM, Munroe RJ, Schimenti JC, Hermeking H, Nikitin AY. Mir-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep. 2014; 6:1000-1007.
24. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB. Microrna-34 mediates ar-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther. 2008; 7:1288-1296.
25. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. Ras oncogenes: Weaving a tumorigenic web. Nat Rev Cancer. 2011; 11:761-774.
26. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011; 144:646-674.
27. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. Kras, braf, pik3ca, and pten mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011; 12:594-603.
28. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 1991; 67:879-888.
29. Placzek WJ, Wei J, Kitada S, Zhai D, Reed JC, Pellecchia M. A survey of the anti-apoptotic bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of bcl-2 antagonists in cancer therapy. Cell Death Dis. 2010; 1:e40.
30. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A. The ras-rasgap complex: Structural basis for gtpase activation and its loss in oncogenic ras mutants. Science. 1997; 277:333-338.
31. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, Barbacid M. Tumor induction by an endogenous k-ras oncogene is highly dependent on cellular context. Cancer Cell. 2003; 4:111-120.
32. Karnoub AE, Weinberg RA. Ras oncogenes: Split personalities. Nat Rev Mol Cell Biol. 2008; 9:517-531.
33. Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M, Kelly K. Activation of the ralgef/ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol. 2007; 27:7538-7550.
34. Yin JJ, Zhang L, Munasinghe J, Linnoila RI, Kelly K. Cediranib/azd2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res. 2010; 70:8662-8673.
35. Pearson HB, Phesse TJ, Clarke AR. K-ras and wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res. 2009; 69:94-101.
36. Hoppler S, Kavanagh CL. Wnt signalling: Variety at the core. J Cell Sci. 2007; 120:385-393.
37. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massague J. Wnt/tcf signaling through lef1 and hoxb9 mediates lung adenocarcinoma metastasis. Cell. 2009; 138:51-62.
38. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogeneinduced DNA damage model for cancer development. Science. 2008; 319:1352-1355.
39. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Transactivation of mir-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26:745-752.
40. Okada N, Lin CP, Ribeiro MC, Biton A, Lai G, He X, Bu P, Vogel H, Jablons DM, Keller AC, Wilkinson JE, He B, Speed TP, He L. A positive feedback between p53 and mir-34 mirnas mediates tumor suppression. Genes Dev. 2014; 28:438-450.
41. Shen Z, Zhan G, Ye D, Ren Y, Cheng L, Wu Z, Guo J. Microrna-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol. 2012; 29:2473-2480.
42. Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Roh S, Hoffmann R, Warscheid B, Hermeking H. Genome-wide characterization of mir-34a induced changes in protein and mrna expression by a combined pulsed silac and microarray analysis. Mol Cell Proteomics. 2011; 10:M111 010462.
43. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell. 2009; 17:9-26.
44. Shiraishi T, Muneyuki T, Fukutome K, Ito H, Kotake T, Watanabe M, Yatani R. Mutations of ras genes are relatively frequent in japanese prostate cancers: Pointing to genetic differences between populations. Anticancer Res. 1998; 18:2789-2792.
45. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of ras signaling restores androgen sensitivity to hormonerefractory c4-2 prostate cancer cells. Cancer Res. 2003; 63:1975-1980.
46. Fan F, Sun A, Zhao H, Liu X, Zhang W, Jin X, Wang C, Ma X, Shen C, Zou Y, Hu K, Ge J. Microrna-34a promotes cardiomyocyte apoptosis post myocardial infarction through down-regulating aldehyde dehydrogenase 2. Curr Pharm Des. 2013; 19:4865-4873.
47. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol. 2002; 21:315-320.
48. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998; 58:5071-5074.
49. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by vegf. Proc Natl Acad Sci U S A. 2002; 99:4349-4354.
50. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999; 341:452-453.
51. Kumar B, Yadav A, Lang J, Teknos TN, Kumar P. Dysregulation of microrna-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One. 2012; 7:e37601.
52. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013; 32:5501-5511.
53. Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, Martin P, Kelly K. Mir-1 and mir-200 inhibit emt via slug-dependent and tumorigenesis via slug-independent mechanisms. Oncogene. 2013; 32:296-306.
54. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC. Systematic rna interference reveals that oncogenic kras-driven cancers require tbk1. Nature. 2009; 462:108-112.
55. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007; 7:64.
56. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545-15550.